The investment objective of the fund is to generate positive and uncorrelated absolute returns in all market conditions over a 12 month period.
Name | % Net Assets |
---|---|
GENENTECH INC (UN*) | 4.3% |
NOVO NORDISK A/S-B (DC*) | 3.3% |
NESTLE SA-REGISTERED (VX*) | 3.0% |
BRITISH AMERICAN TOBACCO PLC | 3.0% |
NATIONAL GRID PLC (LN*) | 2.6% |
GDF SUEZ (FP*) | 2.1% |
TERNA SPA (IM*) | 2.1% |
ACTELION LTD (SE*) | 2.1% |
FRESENIUS MEDICAL CARE (GF) | 2.0% |
NOVARTIS AG-REG SHS (VX*) | 2.0% |
Key | % Net Assets |
---|---|
GENENTECH INC (UN*) | 4.3% |
NOVO NORDISK A/S-B (DC*) | 3.3% |
NESTLE SA-REGISTERED (VX*) | 3.0% |
BRITISH AMERICAN TOBACCO PLC | 3.0% |
Other | 86.4% |
Date | 24-Nov-2017 |
---|---|
NAV | 1.20p |
Currency | GBP |
Change | 0.002p |
% | -0.16% |
YTD change | 1.20p |
YTD % | n/a |
Fund Inception | n/a |
---|---|
Fund Manager | n/a |
TER | 1.88 (31-Dec-2011) |
Minimum Investment | |
---|---|
Initial | n/a |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | n/a |
Exit | n/a |
Name | % |
---|---|
No risk data available. |
You are here: research